AR and prostate cancer: Our recent study shows that targeting PCNA/AR interaction with enzalutamide, PCNA-I1S, R9-AR-PIP, and/or T2AA induces cytotoxicity in both androgen-dependent prostate cancer cells and CRPC cells [54].